truvada
gilead sciences ireland uc - emtrisitabiinin, tenofoviiridisoproksiilifumaraatin - hiv-infektiot - antiviraalit systeemiseen käyttöön - treatment of hiv-1 infection: , truvada is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults. , truvada on myös indikoitu hiv-1-tartunnan saaneille nuorille, joilla on nrti-resistenssi tai toksisia vaikutuksia ei siten voi käyttää ensimmäisen linjan tekijöille, iältään 12 - < 18 vuotta. , pre-exposure prophylaxis (prep): , truvada is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk.
kefolor 50 mg/ml rakeet oraalisuspensiota varten
actavis nordic a/s regulatory affairs - cefaclorum monohydricum - rakeet oraalisuspensiota varten - 50 mg/ml - kefaklori
rocephalin cum lidocain 1 g injektiokuiva-aine ja liuotin, liuosta varten
roche oy - ceftriaxone, lidocaine hydrochloride monohydrate - injektiokuiva-aine ja liuotin, liuosta varten - 1 g - keftriaksoni
azactam injektio-/infuusiokuiva-aine liuosta varten
bristol-myers squibb ab - aztreonam - injektio-/infuusiokuiva-aine liuosta varten - atstreonaami
emtricitabine/tenofovir disoproxil teva 200 mg / 245 mg tabletti, kalvopäällysteinen
teva b.v. - tenofoviri disoproxili phosphas,emtricitabinum - tabletti, kalvopäällysteinen - 200 mg / 245 mg - tenofoviiridisoproksiili ja emtrisitabiini
emtricitabine/tenofovir disoproxil stada 200 mg / 245 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - tenofovir disoproxil succinate, emtricitabine - tabletti, kalvopäällysteinen - 200 mg / 245 mg - tenofoviiridisoproksiili ja emtrisitabiini
emtricitabine/tenofovir disoproxil sandoz 200 mg / 245 mg tabletti, kalvopäällysteinen
sandoz a/s - tenofovir disoproxil, emtricitabine - tabletti, kalvopäällysteinen - 200 mg / 245 mg - tenofoviiridisoproksiili ja emtrisitabiini
emtricitabine/tenofovir disoproxil accord 200 mg / 245 mg tabletti, kalvopäällysteinen
accord healthcare b.v. - tenofovir disoproxil, emtricitabine - tabletti, kalvopäällysteinen - 200 mg / 245 mg - tenofoviiridisoproksiili ja emtrisitabiini
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
ceftriaxon qilu 1 g injektio/infuusiokuiva-aine, liuosta varten
qilu pharma spain s.l. - ceftriaxonum natricum - injektio/infuusiokuiva-aine, liuosta varten - 1 g - keftriaksoni